Chemed reported Q4 FY2025 revenue of USD 639.3 million (flat), with GAAP diluted EPS of USD 5.48 (-9.0%) and adjusted diluted EPS of USD 6.42 (-6.0%). Net income in Q4 was USD 76.8 million. In the VITAS segment, Q4 net patient revenue was USD 418.8 million (+1.9%), average daily census was 22,462 (+1.3%), and admissions were 17,419 (+6.0%). VITAS accrued USD 2.4 million in Medicare Cap billing limitation in Q4, and reported adjusted EBITDA (excluding Medicare Cap) of USD 91.6 million (-1.7%) with a 21.7% adjusted EBITDA margin (excluding Medicare Cap). Chemed said there was no Medicare Cap billing limitation recorded in Q4 related to the Florida combined program. Roto-Rooter Q4 revenue was USD 220.6 million (-3.7%), with adjusted EBITDA of USD 47.5 million (-21.1%) and a 21.5% adjusted EBITDA margin (down 477-basis points). Chemed ended FY2025 with USD 74.5 million of cash and cash equivalents and no current or long-term debt, and repurchased 400,000 shares for USD 174.6 million in Q4. For FY2026, Chemed guided to adjusted diluted EPS of USD 23.25 to USD 24.25 and projected Medicare Cap billing limitations of USD 9.5 million (vs. USD 27.2 million in calendar 2025).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.